Analysis

Zenas Biopharma, Inc. (ZBIO) Stock Analysis

Zenas Biopharma, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to ZBIO.

websiteZBIO/analysis/ZBIO

Zenas Biopharma, Inc.

Zenas Biopharma, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to ZBIO.

Stock profile

Ticker

ZBIO

Asset type

Stock

Market cap

$1.25B

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Zenas Biopharma, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • ZBIO primary listing

Latest Zenas Biopharma, Inc. news

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD),...

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results - - Obexelimab significantly lowered the total amount of glucocorticoid...

Zenas BioPharma Announces Submission of Biologics License Application to U.S. FDA for Obexelimab in IgG4-RD

Zenas BioPharma Announces Submission of Biologics License Application to U.S. FDA for Obexelimab in

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD

- BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the ...

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Re...

Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhi...

- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with p...

Research sections

Valuation

Review valuation context for Zenas Biopharma, Inc..

Future growth

Review future growth context for Zenas Biopharma, Inc..

Past performance

Review past performance context for Zenas Biopharma, Inc..

Financial health

Review financial health context for Zenas Biopharma, Inc..

Dividend

Review dividend context for Zenas Biopharma, Inc..

Management

Review management context for Zenas Biopharma, Inc..

Ownership

Review ownership context for Zenas Biopharma, Inc..

Other information

Review other information context for Zenas Biopharma, Inc..

Community

Review community context for Zenas Biopharma, Inc..